Erlotinib, Bbi-825, Bbi-355, Futibatinib
Small Cell Lung Cancer, Pancreatic Cancer Metastatic, Triple Negative Breast Cancer (Tnbc), Er+ Breast Cancer, Cervical Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma (Cscc), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head And Neck (Hnscc), Leiomyosarcoma (Lms), Undifferentiated Pleomorphic Sarcoma (Ups)
Recruiting
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
―